'19.07.30, ̿Ǿ
1) ̿Ǿǰ , 4 2) Ǿǰ/Ǿǰ ǰ ̿Ǿǰ - Ǿǰ : (1) ̺۷κҸ5% (, ȹ)
(2) (彺, ) - Ǿǰ : (1) 긶 (Ʈ, Ǿǰ)
(2) Ʈø (Ʈ, Ǿǰ) (3) ø (Ʈ, Ǿǰ)
3) '18 Ǿǰ ִ, ̿Ǿǰ 33% - Ǿǰ(ü) 46 7,311(5 1,431)
- ̿Ǿǰ 15 5,925(1 7,161)
- ̿Ǿǰ ֱ5('14~'18) 27.6% , 弼
̿Ǿǰ Ǿǰ(ü) 1/10 , 1/3
4) Ư, ̿ùз Ǿǰ(ü) 23% 尡ɼ |
|
ڷ Point
̿Ǿǰ ü Ǿǰ (12.4%) (33.4%) κп ɼ ũٰ ǴܵǾ, Ư (58.3%) ֿ ⱹ Ÿ ̿Ǿǰ Բ ݵǰ û |
|
彺100/ ġῡ ־ 彺 ϱ, 1 ӻ / ()½۷ι / 2019-07-29 / 1 |
|
LY3434172 / ༺ Ͽ LY3434172 ü ܵ 1 / ѱ / 2019-07-26 / 1 |
|
ؿ ӻ (clnicaltrials.gov 2019.07.23~2019.07.29)
|
|
<̱> Biological: Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo / A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer / Carcinoma, Non-Small-Cell Lung / Bristol-Myers Squibb / NCT04025879 / Phase 3 14
|
|
ؿ 㰡 (clnicaltrials.gov 2019.07.16~2019.07.22)
|
|
HADLIMABLA #761059 / ADALIMUMAB-BWWD / SAMSUNG BIOEPIS CO LTD / 07/23/2019 |
|
RUXIENCEBLA #761103 / RITUXIMAB-PVVR / PFIZER INC / 07/23/2019
|
|
BAQSIMINDA #210134 / GLUCAGON / ſ뷮 / ELI LILLY AND CO / 07/24/2019
|
|
ANGIOMAX RTUNDA #211215 / BIVALIRUDIN / Ǵ / MAIA PHARMS INC / 07/25/2019
|
|
ACCRUFERNDA #212320 / FERRIC MALTOL / Ź ź / SHIELD TX UK LTD / 07/25/2019
|
|
NIFDS - DIA ũ8 21-22 / CV Early Bird ! |
|
̿ õ ۷ι ۷ 2019"̿Ǿ ο "
8 20(ȭ) / ۵ þ 庼 ~8 7(), û() ߽ 4 ô, ǰ Ȳ 㰡 2019 8 22() / ѱ̿ȸ ~8 20(ȭ), û 3 |
|
|
|
|